Journal Basic Info
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.Major Scope
- Paediatric Cancers
- Carcinomas
- Melanoma/Skin Cancer
- Hematology
- Pancreatic Cancer
- Head and Neck Oncology
- Immunotherapy
- Colorectal Cancer
Abstract
Citation: Clin Oncol. 2022;7(1):1930.DOI: 10.25107/2474-1663.1930
Persistent Lymphedema in a Patient with Advanced Gastric Cancer with ERBB3 Mutation
Chen Yang, Dongliang Mao, Qianyun He, Chen Wang and Mei Wang
Department of Oncology, Shanghai Jiao Tong University, China
These authors contributed equally to this work
PDF Full Text Case Report | Open Access
Abstract:
Gastric cancer remains a major global health burden with high recurrence and mortality rates, especially in countries in East Asia. Studies have shown that gastric cancer presenting with lymphedema has poor survival. Furthermore, no standard treatment has been accepted for metastatic gastric cancer with lymphedema. In this report, we present a case of advanced gastric cancer with persistent lymphedema after gastrectomy. ERBB3 V104M mutation was identified by next-generation sequencing. The patient did not have a good response to nivolumab-based treatment with pyrotinib plus chemotherapy. Advanced gastric cancer with refractory lymphedema remains a challenge with immunotherapy based treatment.
Keywords:
Gastric cancer; Lymphedema; Nivolumab; ERBB3; Pyrotinib
Cite the Article:
Yang C, Mao D, He Q, Wang C, Wang M. Persistent Lymphedema in a Patient with Advanced Gastric Cancer with ERBB3 Mutation. Clin Oncol. 2022;7:1930..
